EXHIBIT 99.2

GENENTECH, INC. CONSOLIDATED STATEMENTS OF INCOME DATA (in thousands, except per share amounts) (unaudited)
	Three Months Ended December 31,
		2005		2004
Revenues:
Product sales	$	1,576,964	$	1,066,302
Royalties		265,099		181,220
Contract revenue and other		51,032		67,778
Total operating revenues		1,893,095		1,315,300
Costs and expenses:
Cost of sales		244,914		205,373
Research and development		411,610		310,196
Marketing, general and administrative		429,357		299,495
Collaboration profit sharing		228,417		170,070
Recurring charges related to redemption		26,591		34,534
Special items:  litigation-related		13,483		(3,189)
Total costs and expenses		1,354,372		1,016,479
Operating income		538,723		298,821
Other income (expense):
Interest and other income, net(1)		43,743		24,041
Interest expense		(23,035)		(2,718)
Total other income, net		20,708		21,323
Income before taxes		559,431		320,144
Income tax provision		220,192		113,560
Net income	$	339,239	$	206,584
Earnings per share:
Basic	$	0.32	$	0.20
Diluted	$	0.31	$	0.19
Weighted average shares used to compute earnings per share:
Basic		1,054,724		1,049,700
Diluted		1,080,152		1,070,708

___________________

(1) "Interest and other income, net" includes interest income, net realized gains from the sale of certain biotechnology equity securities and write-downs for other-than-temporary impairments in the fair value of certain biotechnology debt and equity securities. For further detail, refer to our web site at www.gene.com.

- 1 -

GENENTECH, INC. CONSOLIDATED STATEMENTS OF INCOME DATA (in thousands, except per share amounts) (unaudited)
	Year Ended December 31,
		2005		2004
Revenues:
Product sales	$	5,488,058	$	3,748,879
Royalties		935,112		641,119
Contract revenue and other		210,202		231,159
Total operating revenues		6,633,372		4,621,157
Costs and expenses:
Cost of sales(2)		1,011,069		672,526
Research and development		1,261,824		947,513
Marketing, general and administrative(2)		1,435,025		1,088,111
Collaboration profit sharing		823,083		593,616
Recurring charges related to redemption		122,746		145,485
Special items:  litigation-related		57,774		37,087
Total costs and expenses		4,711,521		3,484,338
Operating income		1,921,851		1,136,819
Other income (expense):
Interest and other income, net(1)		140,927		89,997
Interest expense		(49,929)		(7,400)
Total other income, net		90,998		82,597
Income before taxes		2,012,849		1,219,416
Income tax provision		733,858		434,600
Net income	$	1,278,991	$	784,816
Earnings per share:
Basic	$	1.21	$	0.74
Diluted	$	1.18	$	0.73
Weighted average shares used to compute earnings per share:
Basic		1,054,952		1,055,165
Diluted		1,080,949		1,079,209

___________________

(1)	"Interest and other income, net" includes interest income, net realized gains from the sale of certain biotechnology equity securities and write-downs for other-than-temporary impairments in the fair value of certain biotechnology debt and equity securities. For further detail, refer to our web site at www.gene.com.
(2)	Certain minor amounts for the nine months ended September 30, 2005 have been reclassified to conform to the current year-end presentation.

- 2 -

GENENTECH, INC. CONSOLIDATED BALANCE SHEETS DATA (in thousands) (unaudited)
	December 31,
	2005			2004
Selected balance sheet data:
Cash, cash equivalents and short-term investments	$	2,365,161		$	1,665,105
Accounts receivable - product sales, net		554,455			599,052
Accounts receivable - royalties, net		296,664			217,482
Accounts receivable - other, net		232,297			143,421
Inventories		702,515			590,343
Long-term marketable debt and equity securities		1,448,731			1,115,327
Property, plant and equipment, net		3,349,352			2,091,404
Goodwill		1,315,019			1,315,019
Other intangible assets		573,779			668,391
Other long-term assets		1,041,219			787,914
Total assets		12,146,879			9,403,395
Total current liabilities		1,659,832			1,238,030
Total liabilities		4,677,295	(1)		2,621,205
Total stockholders' equity		7,469,584			6,782,190
Year-to-date:
Capital expenditures	$	1,399,824	(2)	$	649,858
Total depreciation and amortization expense		370,166			353,221

___________________

(1)	Includes approximately $2 billion related to our debt issuance in July 2005.
(2)	Excludes approximately $94 million in capitalized costs related to our accounting for a construction project which we are considered to be the owner of during the construction period. We have recognized a corresponding amount as a construction financing obligation in long-term debt.

- 3 -

GENENTECH, INC. NET PRODUCT SALES DETAIL (in thousands) (unaudited)
	Three Months Ended December 31,
	2005		2004
Net U.S. Product Sales
Rituxan	$	484,404	$	429,184
Herceptin		250,069		125,952
Avastin		359,110		190,546
Nutropin products		94,891		91,894
Thrombolytics		58,389		47,300
Pulmozyme		49,008		42,757
Xolair		93,250		60,340
Raptiva		20,453		16,421
Tarceva		83,891		13,348
Total U.S. product sales		1,493,465		1,017,742
Net product sales to collaborators		83,499		48,560
Total Product Sales	$	1,576,964	$	1,066,302
	Year Ended December 31,
	2005		2004
Net U.S. Product Sales
Rituxan	$	1,831,529	$	1,573,997
Herceptin		747,274		478,948
Avastin		1,132,805		544,680
Nutropin products		370,461		348,790
Thrombolytics		218,494		194,433
Pulmozyme		186,490		157,097
Xolair		320,433		187,672
Raptiva		79,256		52,392
Tarceva		274,884		13,348
Total U.S. product sales		5,161,626		3,551,357
Net product sales to collaborators		326,432		197,522
Total Product Sales	$	5,488,058	$	3,748,879

- 4 -